路易体痴呆遗传结构的两阶段全基因组关联研究
该两阶段全基因组关联研究纳入1743例路易体痴呆患者(其中1324例病理诊断)和4454名对照,确认APOE、SNCA和GBA为风险基因,并发现CNTN1为候选新位点,估计路易体痴呆的遗传力约为36%。
要点
- APOE、SNCA和GBA与路易体痴呆显著关联,其中APOE风险最高。
- CNTN1为新候选位点,需进一步复制验证。
- 路易体痴呆的遗传力估计约为36%。
核心结论
- 常见遗传变异在路易体痴呆中起作用,APOE、SNCA和GBA为确认的风险基因。
研究设计与样本
- 两阶段全基因组关联研究,纳入欧洲 ancestry 白人参与者,病例按临床或病理标准诊断。
- 发现阶段:1216例患者 vs 3791名对照;复制阶段:527例 vs 663名对照。
- 总样本:1743例患者(1324例病理诊断)和4454名对照。
主要发现
- 路易体痴呆的遗传力估计约为36%。
临床怎么用
- 对于路易体痴呆的遗传风险评估,可关注APOE、SNCA和GBA等确认位点。
局限性
- 样本量对于全基因组关联研究而言较小。
- 从多个地点 ascertainment 样本可能存在潜在偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dementia with Lewy bodies is the second most common form of dementia in elderly people but has been overshadowed in the research field, partly because of similarities between dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease. So far, to our knowledge, no large-scale genetic study of dementia with Lewy bodies has been done. To better understand the genetic basis of dementia with Lewy bodies, we have done a genome-wide association study with the aim of identifying genetic risk factors for this disorder. METHODS: In this two-stage genome-wide association study, we collected samples from white participants of European ancestry who had been diagnosed with dementia with Lewy bodies according to established clinical or pathological criteria. In the discovery stage (with the case cohort recruited from 22 centres in ten countries and the controls derived from two publicly available database of Genotypes and Phenotypes studies [phs000404.v1.p1 and phs000982.v1.p1] in the USA), we performed genotyping and exploited the recently established Haplotype Reference Consortium panel as the basis for imputation. Pathological samples were ascertained following autopsy in each individual brain bank, whereas clinical samples were collected after participant examination. There was no specific timeframe for collection of samples. We did association analyses in all participants with dementia with Lewy bodies, and also only in participants with pathological diagnosis. In the replication stage, we performed genotyping of significant and suggestive results from the discovery stage. Lastly, we did a meta-analysis of both stages under a fixed-effects model and used logistic regression to test for association in each stage. FINDINGS: This study included 1743 patients with dementia with Lewy bodies (1324 with pathological diagnosis) and 4454 controls (1216 patients with dementia with Lewy bodies vs 3791 controls in the discovery stage; 527 vs 663 in the replication stage). Results confirm previously reported associations: APOE (rs429358; odds ratio [OR] 2·40, 95% CI 2·14-2·70; p=1·05 × 10-48), SNCA (rs7681440; OR 0·73, 0·66-0·81; p=6·39 × 10-10), an GBA (rs35749011; OR 2·55, 1·88-3·46; p=1·78 × 10-9). They also provide some evidence for a novel candidate locus, namely CNTN1 (rs7314908; OR 1·51, 1·27-1·79; p=2·32 × 10-6); further replication will be important. Additionally, we estimate the heritable component of dementia with Lewy bodies to be about 36%. INTERPRETATION: Despite the small sample size for a genome-wide association study, and acknowledging the potential biases from ascertaining samples from multiple locations, we present the most comprehensive and well powered genetic study in dementia with Lewy bodies so far. These data show that common genetic variability has a role in the disease. FUNDING: The Alzheimer's Society and the Lewy Body Society.
引用
- Guerreiro R, Ross OA, Kun-Rodrigues C, et al. Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurol. 2017. PMID: 29263008. doi:10.1016/S1474-4422(17)30400-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。